For instance, filgotinib and upadacitinib, both selective inhibitors of JAK1, are promising candidates in the future, as well as the monoclonal antibody to type I IFN receptor subunit 1 (IFNAR1) anifrolumab, which showed promising effects in systemic lupus erythematosus (27). Here, IFNAR1 is linked to systemic lupus erythematosus.